EPIK-P2: A PHASE II DOUBLE-BLIND STUDY WITH AN UPFRONT, 16-WEEK RANDOMIZED PLACEBO-CONTROLLED PERIOD, TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF ALPELISIB (BYL719) IN PEDIATRIC AND ADULT PATIENTS WITH PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
- Registry ID
- CBYL719F12201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2023-01-13
- Last update
- 2020-12-23
Conditions
- PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
View on source registry